儿童重型再生障碍性贫血临床评估阴性后隐匿性遗传性骨髓衰竭发生率低
该回顾性研究对153例儿童重型再生障碍性贫血(SAA)患者行针对IBMFS基因的增强全外显子测序,其中149例有完整临床和实验室诊断数据。113例(75.8%)无IBMFS临床或实验室特征,均未检出诊断性致病或可能致病变异;36例(24.2%)至少有一项提示IBMFS的临床发现,其中仅2例检出相关变异。结论:当前综合评估阴性的SAA患儿隐匿性IBMFS风险低,等待基因检测的获益需与治疗延迟风险权衡。
要点
- 综合临床和实验室评估阴性的儿童SAA,隐匿性IBMFS风险低。
- 113例无IBMFS临床特征者均未检出诊断性致病或可能致病变异。
- 等待基因检测结果可能延迟SAA治疗,需权衡其风险。
核心结论
- 对采用当前诊断性临床和实验室评估综合检查阴性的SAA患者,隐匿性IBMFS的风险低。
研究设计与样本
- 回顾性研究,对153例SAA患儿行针对IBMFS基因的增强全外显子测序,其中149例有完整临床和实验室诊断数据。
主要发现
- 113例(75.8%)无IBMFS临床或实验室特征,均未检出诊断性致病或可能致病变异。
- 36例(24.2%)至少有一项提示IBMFS的临床发现,其中1例携带SAMD9L杂合致病性变异且临床病史一致。
- 另1例经临床评估提示IBMFS的患者携带两个ERCC6L2致病性变异,但等位基因相位及受影响状态无法确定。
临床怎么用
- 对综合临床和实验室评估阴性的儿童SAA,可考虑不等待基因检测结果而尽早治疗,以降低治疗延迟风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Distinguishing inherited bone marrow failure syndromes (IBMFS) from acquired idiopathic severe aplastic anemia (SAA) impacts treatment decisions and long-term management. The diagnostic evaluation of SAA has evolved with advances in our understanding of IBMFS. The benefit of germline genetic testing to screen for IBMFS in the context of current comprehensive SAA evaluations has not been systematically assessed. Awaiting genetic testing can delay treatment for idiopathic SAA increasing the risk of life-threatening complications. This retrospective study investigates the incidence of cryptic IBMFS among pediatric patients with SAA evaluated with current standard-of-care clinical and laboratory assessments. Enhanced whole exome sequencing tailored to IBMFS genes was conducted for 153 patients with SAA. Comprehensive clinical and laboratory diagnostic data were available for 149 patients. No clinical or laboratory features of an IBMFS were identified in 113 patients (75.8%) and none harbored pathogenic or likely pathogenic variants diagnostic of IBMFS. At least one clinical finding suggestive of an IBMFS was identified in the remaining 36 patients (24.2%). Of these, one harbored a heterozygous pathogenic variant in SAMD9L and had a consistent clinical history. A second patient flagged by clinical evaluation had two pathogenic variants in ERCC6L2, although allelic phasing and therefore affected status could not be determined. For patients with a negative comprehensive workup for SAA utilizing current diagnostic clinical and laboratory evaluations, the risk of a cryptic IBMFS is low. For these patients, the low likelihood of benefit gained by awaiting genetic testing results must be weighed against the risks of treatment delay.
引用
- de Jong, Reed, Gaviria Garrido, et al. Low Incidence of Cryptic Genetic Marrow Failure in Pediatric Severe Aplastic Anemia Following Negative Clinical Workup. Blood. 2026. PMID: 42949905. doi:10.1182/blood.2026034684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。